Summer 2027

Technology Intern

Technology LDP

Updated on 8/24/2026

Deadline 10/19/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$26 - $34/hr

+ Housing stipend

No H1B Sponsorship

West Chester, PA, USA + 10 more

More locations: Horsham, PA, USA | Spring House, PA, USA | New Brunswick, NJ, USA | Irvine, CA, USA | Raritan, NJ, USA | Santa Clara, CA, USA | Hopewell Township, NJ, USA | Fort Washington, PA, USA | Jacksonville, FL, USA | Palm Beach Gardens, FL, USA

Hybrid

Three days on-site and two days remote per week.

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
Agile
Data Visualization
Data Science
Machine Learning
Data Engineering
Infrastructure as Code (IaC)
Cybersecurity
Data Modeling
DevOps
Graphic Design
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Permanently authorized to work in the United States without requiring employment visa sponsorship at application or in the future.
  • Have a cumulative GPA of 3.0 or higher across all college coursework.
  • Be currently enrolled and pursuing a bachelor's or master's degree.
  • By the start date, be an undergraduate sophomore or above.
  • Master's students must have earned their undergraduate degree on or after May 2028.
  • Be able to work full time, 40 hours per week, for the entire internship term.
  • Have a passion for a career in technology.
Responsibilities
  • Work within specialized groups in the J&J Technology organization to build solutions for business partners and drive value.
  • Contribute individually and/or as a team member to support a designated technology area.
  • Work with key stakeholders to accomplish goals and objectives supporting the J&J Technology project and program portfolio.
  • Build awareness and experience of key capability skills supporting the J&J Technology strategy.
  • Conduct data and process analysis to support development of key solutions.
Desired Qualifications
  • Preferred fields include Information Management, Information Technology, Computer Engineering, Management Information Systems, Computer Science, Software Engineering or Software Development, Data Science, Cybersecurity, Graphic Design, or Mathematics.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved IMAAVY for wAIHA on August 24, 2026, opening a new market.
  • Q2 2026 sales reached $25.3 billion, and J&J raised 2026 outlook to $101.1 billion.
  • TECVAYLI plus DARZALEX won FDA approval in March 2026 and strong July 2026 data.

What critics are saying

  • The July 2026 talc deal needs 95% claimant acceptance, or litigation continues.
  • UK talc claims filed in October 2025 remain outside the U.S. settlement.
  • STELARA biosimilar erosion keeps hitting sales while TREMFYA must replace it fast.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals and MedTech, reducing dependence on any single franchise.
  • TREMFYA, DARZALEX, and RYBREVANT create multiple billion-dollar growth engines.
  • Management targets oncology leadership and $50 billion oncology sales by 2030.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.

Yahoo Finance
Aug 26th, 2026
J&J eyes $50B oncology target by 2030 as 96% of portfolio grows 14%

Johnson & Johnson's stock upside is being underestimated as investors focus narrowly on STELARA's patent cliff, according to a new analysis. The drug now represents just 4% of the Innovative Medicine portfolio, whilst the remaining 96% is growing at over 14%. The company operates 28 different billion-dollar platforms, demonstrating diversification beyond single-product dependency. Under baseline assumptions—revenue compounding at 6.8% annually, net margin improving from 22% to 24%, and P/E multiple compressing from 31.3x to 26.6x—the analysis projects upside over three years. If net margin returns to its three-year average of 29%, upside could expand further. The most significant drag comes from multiple compression; holding the P/E flat at current levels would lift total upside to 35%. Management's goal to become the leading oncology company by 2030, targeting over $50 billion in oncology sales, could reshape the growth profile.

Yahoo Finance
Aug 26th, 2026
J&J wins first anemia drug approval but stock slips 1% as investors eye commercial hurdles

Johnson & Johnson has secured the first FDA approval for a treatment specifically targeting warm autoimmune hemolytic anemia, a rare and potentially deadly blood disorder. The drug, Imaavy, can now treat steroid-exposed adults and patients aged 12 or older. In clinical trials involving 115 adults, patients receiving Imaavy were approximately three times more likely than those on placebo to achieve sustained haemoglobin improvement after 24 weeks. The treatment also produced an average haemoglobin increase of one gramme per decilitre after the first week. Despite the regulatory milestone, J&J shares fell roughly 1% to $270.665 on Wednesday. The company generated $25.3 billion in second-quarter sales and raised its annual revenue midpoint to $101.1 billion, making this single indication unlikely to significantly impact near-term results.

Yahoo Finance
Aug 25th, 2026
Louisiana jury awards $10M in talc case, J&J liable for $1.2M amid broader settlement talks

A Louisiana jury awarded $10 million in a mesothelioma case linked to talc exposure, assigning Johnson & Johnson over $1.2 million of the liability. The jury found J&J's talc products unreasonably dangerous and inadequately labelled regarding asbestos risks. The verdict is one of multiple talc trial losses for Johnson & Johnson alongside a proposed $5.5 billion settlement aimed at resolving approximately 76,000 ovarian cancer claims. If the settlement proceeds with sufficient claimant participation, it could reduce legal uncertainty. Despite the legal challenges, Johnson & Johnson reported record quarterly sales supporting its Innovative Medicine and MedTech divisions. The company's narrative projects $120.5 billion revenue and $28.6 billion earnings by 2029, requiring 7.2% yearly revenue growth. Ongoing talc verdicts and potential follow-on cases continue to shape perceptions of the company's legal risk alongside its expanding medicines and MedTech portfolio.

PR Newswire
Aug 24th, 2026
FDA approves IMAAVY as first-ever treatment for warm autoimmune hemolytic anemia

The US Food and Drug Administration has approved IMAAVY (nipocalimab-aahu) as the first treatment specifically for warm autoimmune hemolytic anemia in adults and children aged 12 and older. Johnson & Johnson announced the approval following FDA Priority Review. wAIHA is a rare, life-threatening condition where autoantibodies destroy red blood cells, causing severe anaemia and fatigue. Previously, only corticosteroids and immunosuppressants were available. The approval is based on the Phase 2/3 ENERGY study. Results showed approximately three times as many patients receiving IMAAVY achieved durable haemoglobin levels versus placebo by 24 weeks. Patients demonstrated a mean haemoglobin increase of 1 g/dL at Week 1. IMAAVY is an immunoselective FcRn blocker designed to reduce pathogenic IgG autoantibodies whilst preserving B-cell function. Common side effects included peripheral oedema, diarrhoea, and fever.